<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc.</h2>
    <div class="badge">2025-09-15T20:10:00+00:00</div>
    <ul>
      <li>Caution – CE marked since 2019.</li>
<li>FDA approved in August 2025 as prescription-only device.</li>
<li>Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021.</li>
<li>Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019.</li>
<li>Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc.</li>
<li>8,700,183, 9,415,215, and 9,415,216.</li>
<li>Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=Nyxoah%20Files%20Patent%20Infringement%20Lawsuit%20Against%20Inspire%20Medical%20Systems%2C%20Inc.%0A%E2%80%A2%20Caution%20%E2%80%93%20CE%20marked%20since%202019.%0A%E2%80%A2%20FDA%20approved%20in%20August%202025%20as%20prescription-only%20device.%0A%E2%80%A2%20Nyxoah%20completed%20two%20successful%20IPOs%3A%20on%20Euronext%20Brussels%20in%20September%202020%20and%20NASDAQ%20in%20July%202021.%0A%E2%80%A2%20Following%20the%20successful%20completion%20of%20the%20BLAST%20OSA%20study%2C%20the%20Genio%20system%20received%20its%20European%20CE%20Mark%20in%202019.%0A%E2%80%A2%20Mont-Saint-Guibert%2C%20Belgium%20%E2%80%93%20September%2015%2C%202025%2C%2010%3A10pm%20CET%20%2F%204%3A10pm%20ET%20%E2%80%93%20Nyxoah%20SA%20%28Euronext%20Brussels%2FNasdaq%3A%20NYXH%29%20and%20Nyxoah%2C%20Inc.%0A%E2%80%A2%208%2C700%2C183%2C%209%2C415%2C215%2C%20and%209%2C415%2C216.%0A%E2%80%A2%20Additionally%2C%20these%20risks%20and%20uncertainties%20include%2C%20but%20are%20not%20limited%20to%2C%20the%20risks%20and%20uncertainties%20set%20forth%20in%20the%20%E2%80%9CRisk%20Factors%E2%80%9D%20section%20of%20the%20Company%E2%80%99s%20Annual%20Report%20on%20Form%2020-F%20for%20the%20year%20ended%20December%2031&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fnyxoah-files-patent-infringement-lawsuit-against-inspire-medical-systems-inc%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/nyxoah-files-patent-infringement-lawsuit-201000143.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>